US Bancorp DE Purchases 739 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

US Bancorp DE boosted its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 26.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,576 shares of the medical equipment provider’s stock after acquiring an additional 739 shares during the quarter. US Bancorp DE’s holdings in BioLife Solutions were worth $159,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Millennium Management LLC boosted its position in BioLife Solutions by 323.2% in the first quarter. Millennium Management LLC now owns 458,677 shares of the medical equipment provider’s stock valued at $16,512,000 after buying an additional 350,290 shares in the last quarter. New York State Common Retirement Fund boosted its position in BioLife Solutions by 18.7% in the second quarter. New York State Common Retirement Fund now owns 124,603 shares of the medical equipment provider’s stock valued at $5,546,000 after buying an additional 19,674 shares in the last quarter. Bank of Montreal Can boosted its position in BioLife Solutions by 136.7% in the first quarter. Bank of Montreal Can now owns 127,427 shares of the medical equipment provider’s stock valued at $4,562,000 after buying an additional 73,596 shares in the last quarter. SG Americas Securities LLC boosted its position in BioLife Solutions by 74.3% in the first quarter. SG Americas Securities LLC now owns 6,298 shares of the medical equipment provider’s stock valued at $227,000 after buying an additional 2,685 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its position in BioLife Solutions by 208.5% in the first quarter. Victory Capital Management Inc. now owns 232,777 shares of the medical equipment provider’s stock valued at $8,380,000 after buying an additional 157,330 shares in the last quarter. 68.31% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ BLFS opened at $47.49 on Friday. BioLife Solutions, Inc. has a twelve month low of $24.56 and a twelve month high of $60.67. The firm has a fifty day simple moving average of $49.00 and a 200 day simple moving average of $40.86. The company has a market capitalization of $1.93 billion, a PE ratio of 791.63, a P/E/G ratio of 91.16 and a beta of 1.42. The company has a quick ratio of 3.25, a current ratio of 4.07 and a debt-to-equity ratio of 0.01.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Wednesday, August 11th. The medical equipment provider reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.15). BioLife Solutions had a negative return on equity of 0.07% and a net margin of 4.72%. As a group, equities analysts expect that BioLife Solutions, Inc. will post 0.06 earnings per share for the current fiscal year.

A number of analysts have weighed in on BLFS shares. Northland Securities raised their target price on shares of BioLife Solutions from $55.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, September 2nd. TheStreet upgraded shares of BioLife Solutions from a “d” rating to a “c” rating in a report on Wednesday, September 1st. Cowen lifted their price target on shares of BioLife Solutions from $50.00 to $64.00 and gave the stock an “outperform” rating in a report on Friday, August 13th. KeyCorp lifted their price target on shares of BioLife Solutions from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, August 13th. Finally, Zacks Investment Research lowered shares of BioLife Solutions from a “hold” rating to a “sell” rating in a report on Friday, August 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $56.44.

In other BioLife Solutions news, VP Aby J. Mathew sold 715 shares of BioLife Solutions stock in a transaction on Tuesday, June 29th. The shares were sold at an average price of $43.75, for a total value of $31,281.25. Following the completion of the sale, the vice president now directly owns 209,589 shares of the company’s stock, valued at $9,169,518.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CMO Todd Berard sold 6,165 shares of BioLife Solutions stock in a transaction on Thursday, July 15th. The shares were sold at an average price of $42.74, for a total transaction of $263,492.10. The disclosure for this sale can be found here. Insiders have sold 217,275 shares of company stock valued at $10,178,442 in the last three months. 5.90% of the stock is owned by insiders.

BioLife Solutions Profile

BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.

Featured Article: Debt-To-Equity Ratio

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFS).

Institutional Ownership by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.